D.E. Shaw & Co
TNYA icon

D.E. Shaw & Co’s Tenaya Therapeutics TNYA Stock Holding History

D.E. Shaw & Co’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-126,497
Closed -$244K – 4878
2024
Q3 		$244K Buy
+126,497
New +$357K ﹤0.01% 4071
2024
Q1 		– Sell
-95,567
Closed -$310K – 4747
2023
Q4 		$310K Sell
95,567
-29,073
-23% -$62.8K ﹤0.01% 3739
2023
Q3 		$318K Buy
124,640
+37,328
+43% +$156K ﹤0.01% 3595
2023
Q2 		$513K Buy
87,312
+75,478
+638% +$439K ﹤0.01% 3417
2023
Q1 		$33.7K Sell
11,834
-26,002
-69% -$73.1K ﹤0.01% 4082
2022
Q4 		$76K Buy
37,836
+9,552
+34% +$23.3K ﹤0.01% 4403
2022
Q3 		$82K Buy
28,284
+2,844
+11% +$13.3K ﹤0.01% 4625
2022
Q2 		$143K Sell
25,440
-13,076
-34% -$106K ﹤0.01% 4661
2022
Q1 		$454K Buy
+38,516
New +$466K ﹤0.01% 4429

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

D.E. Shaw & Co's TNYA Position: Q4 2024 in Review

D.E. Shaw & Co sold out of Tenaya Therapeutics (TNYA) in Q4 2024, closing a stake of 126,497 shares — an estimated $244K sold.

D.E. Shaw & Co first reported a position in TNYA in Q1 2022 and held it in 9 quarters. The position peaked at $513K in Q2 2023. 88 funds tracked by Wall St. Rank hold TNYA as of Q4 2024.

  • D.E. Shaw & Co reported no remaining Tenaya Therapeutics position as of Q4 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 126,497 Tenaya Therapeutics shares in Q4 2024, an estimated $244K.
  • D.E. Shaw & Co first reported a position in Tenaya Therapeutics in Q1 2022 and held it in 9 quarters.
  • D.E. Shaw & Co's Tenaya Therapeutics position peaked at $513K in Q2 2023.
  • 88 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.